eShowcase: Velos eResearch Version 7
New clinical trial software version provides direct data capture at investigator sites
New clinical trial software version provides direct data capture at investigator sites
Velos, Inc. (Fremont, CA) has released Velos eResearch Version 7 for increased features and functions for large investigative sites. Velos eResearch is a clinical trial management software system.
Velos eResearch Version 7 provides direct capture of clinical trial data, eliminating duplicate data entry. This in turn allows the systems used at the site to generate better or higher quality research data, and offer improved efficiency and productivity for investigators and sponsors.
Velos eResearch 7 uses Web 2.0 technology and system design. It features HL7 compliance, support for study administration, clinical data management, adverse event reporting, compliance with industry standards (including CFR Part 11), patient- and study-level architecture, and advanced security to large multi-institutional clinical studies.
Velos, Inc., (510) 739-4010, www.velos.com
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
